The relationship between the incision line and position of the latissimus dorsi muscle for subcutaneous implantable cardioverter-defibrillator intermuscular implantations.
defibrillation threshold
implantable cardioverter-defibrillator
incision line
intermuscular implantation
latissimus dorsi muscle
subcutaneous implantable cardioverter-defibrillator
ventricular fibrillation
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
12
05
2023
received:
30
12
2022
accepted:
31
05
2023
medline:
11
7
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Intermuscular implantations of subcutaneous implantable cardioverter-defibrillators (S-ICD) have been recommended, but the position of the anterior border of the latissimus dorsi muscle (LDM) has not previously been evaluated in establishing an incision line to facilitate the intermuscular approach. The objective of this study is to evalua the position and trend of the anterior border of the LDM in patients who are candidates for implantable cardioverter-defibrillators. The distance from the back to the anterior border of the LDM (A) and the anterior-posterior width of the chest wall (B) were measured on computed tomography retrospectively, and the ratio (=A/B) was used as the position of the anterior border of the LDM. In addition, the variability and factors affecting the values were evaluated. An analysis was performed on 78 patients, and the position of the anterior border of the LDM (=A/B) exhibited a normal distribution, with a mean value of 0.53 ± 0.062 (0.41-0.69). The position of the anterior border of the LDM tended to be more anterior in younger, taller, male, primary prevention, nonheart failure, low brain natriuretic peptide level, and nondiabetic patients. The position of the anterior border of the LDM varied from case to case with variable results. Conventional incisions on the midaxillary line may be inappropriate for intermuscular implantations, and the position of the anterior border of the LDM should be evaluated in each individual case to establish the incision line.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1569-1576Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944-953.
Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator. J Am Coll Cardiol. 2015;65:1605-1615.
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36-44.
Heist EK, Belalcazar A, Stahl W, Brouwer TF, Knops RE. Determinants of subcutaneous implantable cardioverter-defibrillator efficacy. JACC: Clin Electrophysiol. 2017; 3(4):405-414.
Quast AFBE, Baalman SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: the PRAETORIAN score. Heart Rhythm. 2019;16(3):403-410.
Quast AFBE, Baalman SWE, Van der Stuijt W, Wilde AAM, Knops RE. Minimal defibrillation thresholds and the correlation with implant position in subcutaneous implantable-defibrillator patients. J Cardiovasc Electrophysiol. 2019;30(11):2441-2447.
Biffi M, Bongiorni MG, D'Onofrio A, et al. Is 40 joules enough to successfully defibrillate with subcutaneous implantable cardioverter-defibrillators? JACC: Clin Electrophysiol. 2021;7(6):767-776.
Sonoda Y, Fukuzawa K, Izawa Y, Sakai J, Hirata K. Ultrasound-guided intermuscular pocket creation for a subcutaneous implantable cardioverter-defibrillator. HeartRhythm Case Rep. 2022;8(2):137-141.
Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260.
Abe T. Sex differences in whole body skeletal muscle mass measured by magnetic resonance imaging and its distribution in young Japanese adults. Br J Sports Med. 2003;37(5):436-440.
Suzuki T, Palus S, Springer J. Skeletal muscle wasting in chronic heart failure. ESC Heart Failure. 2018;5(6):1099-1107.
Perry BD, Caldow MK, Brennan-Speranza TC, et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. Exerc Immunol Rev. 2016;22:94-109.
Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14(10):1456-1463.
Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol. 2016;68(19):2047-2055.
Knops RE, Brouwer TF, Barr CS, et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2016;18:1010-1015.